Advertisement

ABP

Abpro Corporation

Healthcare · USD

Set alert

Price alert · ABP

All alert types
0.52 USD 0.00 0.00%
As of Mar 9, 2026
Bid
0.52 × 1
Ask
0.53 × 1
0.522 Day range 0.759
0.95 52-week range 13.00
YTD
-87.66%
1 year
-92.43%
Open
0.759
Prev close
0.522
Mkt cap
124.68M
Vol
1.33M
Avg vol
599.22K
EPS
-0.32
P/E
0.00
Div yield
0.00%
More statistics
Low
0.522
High
0.759
Forward P/E
0.00
Beta
0.00
Short ratio
0.13
Inst. own
0.75%
Dividend
0.00
Ex-div date
50-d avg
6.19
200-d avg
9.88
1y target
0.00

2Y chart

Chart tools
Interval
ABP two-year price chart0.0966.1132.0198.0264.0Nov 24Feb 25May 25Sep 25Dec 25Mar 26

Key statistics

Market cap
124.68M
Enterprise value
107.27M
Trailing P/E
0.00
Forward P/E
0.00
PEG ratio
0.00
Price / sales
1731.60
Price / book
0.00
EPS (TTM)
-0.32
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
72.00K
Revenue growth
0.00%
Free cash flow
0
Total cash
63.00K
Total debt
6.28M
Return on equity
0.00%
Shares outstanding
51.52M
Short % of float
0.00%
50-day average
6.19
200-day average
9.88

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
ABP Revenue — quarterly 0
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025
ABP Net income — quarterly -1.66M
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025
ABP EPS — quarterly -0.63
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025

About Abpro Corporation

Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
abpro.com

News

Your note

Sign in to keep a note on ABP — it syncs with the Stock Master app.

Insider holders

ABP insider holders
InsiderRelationLatest transactionDateShares held
CHAN IANChief Executive OfficerStock Award(Grant)Nov 12, 20240
DOVE BRYANDirectorConversion of Exercise of derivative securityApr 17, 202350,000
KAHLON IQBALJITDirectorConversion of Exercise of derivative securityApr 17, 202350,000
LORD JOANNADirectorConversion of Exercise of derivative securityApr 17, 202350,000
SCHIANO DOMINICK J.DirectorConversion of Exercise of derivative securityApr 17, 202350,000
STANWOOD DARRENDirectorConversion of Exercise of derivative securityApr 17, 202350,000
Advertisement